We retrospectively analyzed the characteristics of 16 consecutive pediatric patients who received one or more G-CSF-mobilized donor lymphocyte infusions (DLI) following a T-cell-depleted haplocompatible hematopoietic SCT (HSCT) to enhance immune recovery and/ or treat an infection. The median time from HSCT to administration of first DLI was 12 weeks and the median dose of DLI administered was 3 Â 10 4 /kg (range, 2.5-6 Â 10 4 /kg). The incidence of Grade I-II acute GVHD was 19% (95% confidence interval (CI), 6-44%), and there were no cases of Grade III-IV acute GVHD. Chronic GVHD developed in 13% (95% CI, 2-37%) of patients. In surviving patients who did not undergo a second stem cell infusion, T-cell numbers and function increased to a protective level in a median of 3 months (range, 2-12.5 months) following the first DLI administration. In patients given DLI for treatment of an infection, 75% (95% CI, 46-92%) cleared their infection after a median of 9 weeks (range, 1-27 weeks). In patients with CMV infection, the development of CMV-specific T cells was observed following DLI. The 1-year overall survival following haplocompatible DLI was 71% (95% CI, 59-83%), with a median follow-up of 16 months from the first DLI.
Introduction
Haplocompatible-related donor hematopoietic SCT (HSCT) has become a viable option for patients with lifethreatening hematologic diseases for whom a matched related or closely matched unrelated donor cannot be identified, 1, 2 or for patients with SCID for whom a lengthy unrelated donor search is not ideal. 3 Haplocompatible donors share a single HLA haplotype with the transplant recipient. Due to the HLA disparities involved, most haplocompatible HSCT protocols utilize ex vivo T-cell depletion to avoid severe GVHD. Low numbers of infused T cells result in limited passive transfer of immunity and slow immune reconstitution, which is related to a high frequency of infectious complications and relapse.
Allogeneic donor lymphocyte infusions (DLI) can accelerate immune reconstitution, treat infections and provide a graft-vs-malignancy effect. 4, 5 Numerous studies have established that the dose of DLI that can be safely administered in the setting of an HLA-identical related HSCT is between 1 Â 10 7 and 1 Â 10 8 CD3 þ cells/kg. 5 Generally, studies evaluating DLI in the matched unrelated donor setting have utilized a 10-fold lower dose of 1 Â 10 6 CD3 þ cells/kg. 5 The optimal safe dose of DLI that can be administered in the haplocompatible setting is less clear, as only a few reports with small numbers of patients exist on the administration of haplocompatible DLI. 1, [6] [7] [8] [9] [10] The source of the T cells utilized for haplocompatible DLI may be important in terms of eventual outcome because of the toleragenic influence of G-CSF on T-cell function. 11 In some reports it is clear that the DLI originated from the cryopreserved CD34À fraction following processing of G-CSF-mobilized PBSC, 9 whereas in other reports the DLI appears to have been obtained from nonmobilized blood collected from the donor after HSCT, [6] [7] [8] or is not specified. 1, 10 To determine the safety of haplocompatible DLI, we retrospectively analyzed the clinical and immunologic outcomes of 16 pediatric patients who received G-CSF-mobilized haplocompatible DLI at our two centers.
Patients and methods

Patients and donors
Medical records of all pediatric patients who were treated on prospective institutional review board (IRB)-approved trials of haplocompatible-related donor HSCT at the University of California, San Francisco Children's Hospital and the University of North Carolina were retrospectively reviewed to identify recipients of post-HSCT DLI because the primary and secondary endpoints of the trials did not include analysis of haplocompatible DLI outcomes. All recipients of DLI were included in the analysis. Patient characteristics at the time of transplant are shown in Table 1 . High-resolution typing was performed at HLA-A, -B, -C, -DRB1 and -DQB1 (except as noted). KIR typing and natural killer (NK) cell alloreactivity were not routinely tested, but HLA Cw predictive alloreactivity for recipient and donor was analyzed when HLA-C typing was available. Donors were considered able to exert donor-vsrecipient NK cell alloreactivity when the recipient did not possess one HLA-C allele group (C1 or C2) present in the donor. 12 
Conditioning
The conditioning regimens are detailed in Table 1 . Primary immunodeficiency patients were treated on successive IRBapproved prospective trials in which the exact conditioning regimen was decided by the presence of a preexisting severe infection at the time of transplant, the presence of maternal engraftment and the immunodeficiency phenotype. 13 In one patient with NEMO syndrome (hypohidrotic ectodermal dysplasia with immunodeficiency), fludarabine (1.33-mg/ kg/dose on days À7 to À3), melphalan (2.33 mg/kg/dose on days À2 and À1) and ATG (0.5 mg/kg on day À5 and 1 mg/kg on day À4) was used.
Nonprimary immunodeficiency patients were treated on a two-center IRB-approved prospective trial in which the conditioning regimen consisted of TBI 1200 cGy given as 200 cGy fractions twice daily on days À9 to À7, 5 mg/kg/ dose of thiotepa (on day À6), 40 mg/m 2 /dose of fludarabine (on days À6 to À2) and rabbit ATG (0.5 mg/kg on day À5, then 1 mg/kg on days À4 to À2). The TBI dose was modified for two patients (Table 1) , one with ALL and one who had received irradiation earlier. One patient rejected his first transplant with protocol conditioning, and received a second transplant from his other parent with additional fludarabine (30 mg/m 2 /dose on days À4 to À2), CY (1000 mg/m 2 on days À3 and À2) and alemtuzumab (10 mg on day À11, 15 mg on day À10 and 20 mg on day À9).
As some patients received myeloablative regimens and some received reduced intensity regimens (Table 1) , univariate analysis was performed to compare outcomes between these two groups. There was no difference noted in the incidence of acute or chronic GVHD, time to immune reconstitution or overall survival (OS), so the outcomes of the two groups were combined.
The patients received no post-transplant GVHD prophylaxis.
Donor PBSC collection and manipulation
Beginning on the evening of day À5 of conditioning, the donors received 8 doses G-CSF s.c. (5 mg/kg/dose) every 12 h for 4 days.
14 On the afternoon of day À1 of conditioning, the donors underwent apheresis. A minimum For SCID patients, CD34 þ cells were positively selected using the Baxter Isolex 300i System (Baxter Healthcare, Deerfield, MA, USA), following which the anti-CD34-bead complex was eluted from the cells and removed. OKT3, an anti-T-cell MoAb, was then added to the cell preparation followed by Dynal sheep anti-mouse magnetic beads. The cell preparation was reexposed to the magnetic field to remove residual CD3 þ cells. For non-SCID patients, CD34 þ cells were positively selected using the CliniMACs (Miltenyi Biotec, Bisley, United Kingdom) System. Different systems were utilized for CD34 selection due to FDA requirements at the time of initiation of the respective trials.
CD34 þ cells were counted utilizing a phycoerythrin (PE)-conjugated MoAb against CD34 and a FITCconjugated MoAb against CD45, then run on a FACScan flow cytometer (Becton-Dickinson, San Jose, CA, USA). 7-Amino-actinomycin D was added so that gating was performed on only viable cells. The gating strategy was based on the International Society of Hemotherapy and Graft Engineering method. 15 Stem cells had low side scatter, low-to-intermediate forward scatter and low-tointermediate amounts of CD45 expression.
The goal for the infused CD34 dose was X20 Â 10 6 /kg of recipient body weight, though in some cases this was not achieved. Actual cell doses infused are shown in Table 1 . The goal for the infused CD3 dose was 3 Â 10 4 /kg for non-SCID patients, 6 Â 10 4 /kg for SCID patients without maternal engraftment and o1 Â 10 4 /kg for SCID patients with maternal engraftment. The resulting mononuclear CD34 þ fraction cells were tested for the presence of T cells by utilizing a PE-conjugated MoAb against CD3 and run on a FACScan flow cytometer. As the level of CD3 depletion differs between the Isolex and CliniMACs, if the CD3 count was above the goal dose, an additional cycle of T-cell depletion was performed. If the CD3 count was below the goal dose, then CD3 þ cells were added from the CD34À fraction product. The protocol lead investigator (MJC) analyzed the initial laboratory methodology at both institutions to ensure that comparable levels of CD34 þ and CD3 þ cells were administered to all patients.
Infection prophylaxis, monitoring and definitions T-cell reconstitution was defined as an absolute CD4 count X200 cells/ml and a phytohemagluttinin (PHA) response X50% of control. Patients were given prophylaxis against Pneumocystis jirovecii with cotrimoxazole (5 mg/kg/day of trimethoprim component divided twice daily for 3 consecutive days per week) until T-cell reconstitution. CMVpositive patients received prophylaxis against reactivation with foscarnet (60 mg/kg/dose twice daily) starting on day þ 1 until day þ 21. All patients received acyclovir (500 mg/ m 2 /dose by mouth three times per day) for Herpes family virus prophylaxis from day 0 (CMV-negative) or day þ 21 (CMV-positive) until T-cell reconstitution. All patients received IVIG (400 mg/kg) every 3-4 weeks until the IgM was 450 mg/100 ml and the isohemaglutinin titers were 1:8 or greater. CMV Ag or PCR monitoring was performed weekly until discharge and then every 2 weeks until T-cell reconstitution. EBV PCR was obtained every 2 weeks until 3 months post-HSCT.
Uncontrolled infection was defined as a viral or fungal infection of the blood or deep organs (primarily lungs) that did not respond to X1 week of appropriate therapy. Time to clearance of infection was defined as the first of three successive negative measurements taken at least 1 week apart.
Donor lymphocyte infusions DLI were prospectively prepared from the negative fraction of the CD34 þ selection by cryopreserving aliquots of 10 Â 10 4 CD3 þ cells/kg. CD3 þ cells were measured as described above. Therefore, these CD3 þ cells were harvested during G-CSF mobilization.
For nonprimary immunodeficiency patients, at the 12-week evaluation, if the absolute CD4 count was less than 100 cells/mm 3 and there was no evidence of active GVHD, a prophylactic infusion of 3 Â 10 4 cryopreserved donor CD3 þ cells/kg was performed. For primary immunodeficiency patients, DLI could be administered as early as 4 weeks post-HSCT if there were no detectible CD4 þ cells. The infusions were repeated at 4-week intervals until the absolute CD4 count was greater than 100 cells/mm 3 , as long as there was no evidence of GVHD.
Earlier infusion of DLI was permitted in the setting of uncontrolled infection and these could be repeated every 4 weeks until evidence of clearing infection. Subsequent DLI doses could be escalated (4-6 Â 10 4 CD3 þ cells/kg) if the patient had previously tolerated, but did not appear to respond, to the lower dosage.
Acute and chronic GHVD following HSCT and DLI were graded using standard criteria.
16,17
Statistics Event-free survival (EFS) and OS were estimated by the Kaplan-Meier method using log-rank tests (SPSS 16.0, SPSS Inc., Chicago, IL, USA). Events were defined as relapse, second transplant or death.
Results
Patients
A total of 16 patients received 1 or more (range, 1-7) infusions of haplocompatible DLI following HSCT, as detailed in Table 2 . Of them, 10 patients were transplanted for treatment of a high-risk malignancy or severe aplastic anemia and 6 patients underwent transplant for treatment of a primary immunodeficiency. The median time from HSCT to the administration of the first DLI was 12 weeks (range, 4-34 weeks). One patient (SF-1141) received DLI earlier than specified, in violation of protocol guidelines. No patient had an absolute CD4 count 4200 cells/ml or a PHA response X50% of control before DLI. The median dose of DLI administered was 3 Â 10 4 /kg (range, 2.5-6 Â 10 4 /kg). 
Adverse effects
Of the 16 patients who received haplocompatible DLI, only 3 patients (19%; 95% confidence interval (CI), 6-44%) showed evidence of Grade I-II acute GVHD. There were no cases of Grade III or IV acute GVHD noted. In addition, one patient (UPN NC-006) developed high fever and hypoxia on day þ 19 following DLI, similar to the possible hyperacute GVHD seen initially following his HSCT. His symptoms resolved promptly with corticosteroids. This patient had predictive NK alloreactivity, as did one other patient without evidence of GVHD. Of the three patients with definitive acute GVHD, two did not have data on NK cell alloreactivity and one was predicted to not have NK cell alloreactivity. Of the 15 patients (13%; 95% CI, 3-39%) surviving for more than 3 months following DLI, 2 went on to develop chronic GVHD. In addition, one patient (UPN NC-010) developed an Ab-positive autoimmune thrombocytopenia and eosinophilia 4.5 months after DLI. This patient had previously been noted to have Grade II acute GVHD (Stage III skin) following HSCT.
Effects of DLI on immune reconstitution
The effect of DLI on immune reconstitution was measured by the amount of time from the last DLI needed for the absolute CD4 count to consistently reach 4200 cells/ml and for the PHA response to be 450% of control. One patient with SCID (UPN SF-1263) did not recover adequate T-cell numbers despite four DLIs and was given a nonconditioned boost donor infusion of 20 Â 10 6 CD34 þ cells/kg plus 6 Â 10 4 CD3 þ cells/kg. He is now 5 months postboost with a normal CD4 count and PHA response, without evidence of infection or GVHD. Four patients never reached a CD4 count of 4200 cells/ml before experiencing a relapse of their disease or expiring due to infection. For the 11 patients that did reach a CD4 count 4200 cells/ml, it took a median of 3 months (range, 1.5-10 months) following the first DLI. Seven patients never reached a PHA response of 450% of control before receiving a boost, experiencing a relapse of their disease or expiring due to infection. For the nine patients that did reach a PHA response of 450% of control, it took a median of 3 months (range, 2-12.5 months) following the first DLI.
Effects of DLI on infection clearance
As seen in Table 2 , 12 of the 16 patients were given DLI for treatment of a viral (n ¼ 11) or combined Nocardia/ Paecilomyces spp. (n ¼ 1) infection; 9 of the 12 patients (75%; 95% CI, 46-92%) successfully cleared their infection at a median of 9 weeks (range, 1-27 weeks) from the time of the last DLI. Direct improvement in CMV copy numbers were seen immediately after DLI administration in two patients (Figure 1) . In patient UPN SF-458, this coincided with the development of CMV-specific T cells (0.23% of all CD4 þ T cells), as measured by in vitro IFN-g production following stimulation with CMV lysate. 18 Of the three patients who did not clear their CMV infection, two subsequently expired due to progressive CMV and one (UPN SF-1145) cleared CMV encephalitis after receiving experimental CMV-specific T cells. 19 It should be noted that two of the three patients who were unable to clear CMV following DLI administration received lymphocytes from a CMV-negative donor. Despite successful clearance of the infections noted at the time of DLI administration, three patients later expired due to the development of new bacterial or fungal infections.
Outcome
For the 16 patients in this study, the 1-year EFS following haplocompatible DLI was 59% (95% CI, 46-72%). One patient with recurrent MDS is alive and in remission 9 months following a second T-cell-depleted haplocompatible HSCT, and one patient with SCID is alive and well 5 months following a nonconditioned boost transplant. Therefore, the 1-year OS is 71% (95% CI, 59-83%). In surviving patients, the median follow-up from date of first DLI is 20 months (range, 6-76 months).
Discussion
In this study we have demonstrated that adoptive immunotherapy with G-CSF-mobilized haplocompatible T cells is feasible and generally safe at a dose level of 3 Â 10 4 CD3 þ cells/kg. A relative paucity of data exists in the literature regarding experience administering haplocompatible DLI, and the informative reports are summarized in Table 3 . 1, [6] [7] [8] [9] [10] In addition to those listed in Table 3 , several other reports exist. Kawano et al. 20 describe administration of an unknown dose of prophylactic G-CSF-mobilized haplocompatible DLI to four pediatric patients, all of whom developed Grade I to Grade IV GVHD and ultimately expired from relapse or infection. Aversa, et al. 2 reported administration of haplocompatible DLI to six patients for treatment of relapsed leukemia, but the dose administered and degree of post-DLI GVHD was not fully described. Although earlier reports utilized relatively high The source of the T cells utilized for haplocompatible DLI may be important in terms of eventual outcome because of the influence of G-CSF on T-cell function. It has been demonstrated that one reason traditional T-replete PBSC transplants have similar rates of acute GVHD compared to transplants of T-replete BM stem cells is that pretreatment of donors with G-CSF polarizes donor T cells toward the production of toleragenic type-2 cytokines (IL-4 and IL-10). 11 The subsequent reduced type-1 cytokine production (IL-2, IFN-g and TNF-a) leads to a reduced severity of acute GVHD, despite an average 10-fold higher number of T cells in the product. 11, 21 Similarly, it would be expected that haplocompatible T cells obtained from the CD34À fraction following G-CSF mobilization will result in less GVHD than T cells collected from the donor without previous administration of G-CSF. This may partly explain the low incidence of acute GVHD in our cohort.
However, Lewalle et al. 9 reported a dose-finding study of G-CSF-mobilized haplocompatible DLI in 11 adults. They found that administration of 1 Â 10 4 CD3 þ cells/kg starting 1 month post-HSCT was well tolerated in nine patients, four of whom developed Grade I to Grade III GVHD. A higher dose of 3 Â 10 4 CD3 þ cells/kg produced Grade II GVHD in two patients, both of whom ultimately expired from complications of chronic GVHD. One potential explanation for this difference is that the majority of our patients were given their first DLI 12 weeks or more from HSCT. This may represent a significantly different clinical milieu, further from the tissue damage induced by conditioning, into which potentially alloreactive lymphocytes are introduced. Another potential explanation is that all of our patients were young, with the majority less than 5 years of age. It has previously been demonstrated that in the setting of HLA-matched sibling transplants, acute GVHD is significantly less common in patients less than 18 years of age. 22 Similarly, it has been shown that chronic GVHD is significantly less common in patients less than 5 years of age. 23 Although the incidence of acute GVHD was low in this cohort, and all cases were confined to Grade I-II, one patient may have experienced an atypical hyperacute GVHD that could not be scored by classic grading criteria. Clinicians administering haplocompatible DLI should monitor for the development of this uncommon potential complication, as hyperacute GVHD has been previously reported following even-matched related donor DLI. 24 The ability of this study to conclusively demonstrate the efficacy of haplocompatible DLI is limited by the small size and lack of untreated controls. Nevertheless, in the majority of patients, the administration of DLI may be associated with slow but definite clearance of life-threatening infections present at the time of DLI. Similarly, the majority of patients did not develop new life-threatening infections after administration of DLI. These results are similar to the effects reported by Lewalle et al. 9 utilizing a slightly smaller dose of 1 Â 10 4 /kg haplocompatible DLI, in which it took a median of 8 weeks (range, 6-14 weeks) for the CD4 count to reach 100 cells/ml after their DLI administration, but did not provide data on the functional reconstitution of T-cell immunity. 9 In our cohort, it took a median of 3 months from the first DLI for both the CD4 count to reach 200 cells/ml and for the PHA response to Table 3 Summary of published experience with haplocompatible DLI reach 450% of control. The kinetics of these more clinically relevant endpoints are similar to those reported for T-cell-depleted BM boosts for treatment of delayed T-cell reconstitution following haplocompatible transplant 25 and equal or superior to that seen following haplocompatible HSCT without DLI. 26, 27 Two alternatives to administration of nonspecific G-CSF-mobilized DLI include pathogen-specific T cells and alloreactive-depleted T cells. The use of pathogenspecific T cells is limited by the repertoire of available Ag. To date, success has been achieved with the creation of T cells specific for CMV, 19, 28, 29 EBV, 29,30 adenovirus 29 and aspergillus. 28 Another approach involves depleting the DLI of alloreactive cells via exposure to anti-CD25. 31, 32 These techniques require significant ex vivo manipulation of the donor cells, and must be initiated 6 weeks before generation of the DLI. Therefore, until pathogen-specific T cells and/ or alloreactive-depleted T cells are more readily available, unmanipulated, nonspecific DLI will continue to play a role in the treatment of poor immune reconstitution and uncontrolled infections following haplocompatible HSCT.
In conclusion, our study demonstrates that administration of G-CSF-mobilized haplocompatible DLI at a dose of 3 Â 10 4 CD3 þ cells/kg is feasible and safe in pediatric patients. Although this study was not intended to prove that administration of DLI improves recipient immune reconstitution, the majority of patients had an excellent clinical outcome following DLI, with either clearance of preexisting infections or protection from development of new infections. This dose may serve as a starting point for future dose-finding trials of G-CSF-mobilized haplocompatible DLI in pediatric recipients.
